0000000000236837

AUTHOR

Rubén Francés

showing 5 related works from this author

Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease W…

2020

HEPAmet Registry.

AdultLiver CirrhosisMalemedicine.medical_specialtySteatosis[SDV]Life Sciences [q-bio]BiopsyLikelihood ratios in diagnostic testingGastroenterologySeverity of Illness IndexDecision Support Techniques03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseasePositive predicative valueInternal medicineNonalcoholic fatty liver diseaseHOMAMedicineHumansComputingMilieux_MISCELLANEOUSAged2. Zero hungerNASH FIBROSISHepatologymedicine.diagnostic_testReceiver operating characteristicbusiness.industryPrognostic FactorGastroenterologyOdds ratioMiddle Agedmedicine.diseasePrognosis3. Good healthCross-Sectional StudiesDiagnostic ToolCirrhosisLiver030220 oncology & carcinogenesisLiver biopsyDiagnostic odds ratio030211 gastroenterology & hepatologyFemalebusinessClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
researchProduct

Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry

2021

Abstract Background and Aims The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed in clinical practice. We aimed to evaluate the durability, effectiveness, and safety of ustekinumab in UC in real life. Methods Patients included in the prospectively maintained ENEIDA registry, who received at least one intravenous dose of ustekinumab due to active UC [Partial Mayo Score [PMS]>2], were included. Clinical activity and effectiveness were defined based on PMS. Short-term response was assessed at Week 16. Results A total of 95 patients were included. At Week 16, 53% of patients had response [including 35% o…

Malemedicine.medical_specialtyustekinumabVedolizumab03 medical and health sciences0302 clinical medicineremissionColitis ulcerosaInternal medicineUstekinumabHumansMedicineProspective StudiesRegistriesInfusions IntravenousAdverse effectreal-world evidenceAcademicSubjects/MED00260ulcerative colitisTofacitinibresponsebiologybusiness.industryRemission InductionC-reactive proteinGastroenterologyGeneral MedicineMiddle Agedmedicine.diseaseUlcerative colitisDiscontinuation030220 oncology & carcinogenesisCohortbiology.proteindurabilityOriginal ArticleColitis UlcerativeFemaleMonoclonal antibodies030211 gastroenterology & hepatologyUstekinumabbusinessAnticossos monoclonalsmedicine.drug
researchProduct

P630 Inflammatory bowel disease in immigrants to Spain: results of the EIIMIGRA study from GETECCU (ENEIDA registry)

2021

Abstract Background Previous studies comparing inflammatory bowel disease(IBD) features between migrant and native patients have shown clinical phenotype differences. To date, no study has focused on IBD immigrants(MP) in Spain. The aim of this study was to explore the features of MP in Spain and to compare age of disease onset, IBD phenotype and therapeutic requirements with native-born IBD patients(NP). Methods This was an observational, multicentric and case-control study of the nationwide ENEIDA registry. We selected all IBD patients who were born outside of Spain and compared with a control cohort of NP. All included patients were diagnosed with IBD before 2015. Results A total of 13,5…

medicine.medical_specialtybusiness.industrymedia_common.quotation_subjectInternal medicineImmigrationGastroenterologymedicineGeneral Medicinemedicine.diseasebusinessInflammatory bowel diseasemedia_commonJournal of Crohn's and Colitis
researchProduct

Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis.

2008

We tested the hypothesis that the presence of bacterial DNA (bactDNA) in ascitic fluid and serum is associated with decreased survival in patients with cirrhosis. In a prospective, multicenter study, we analyzed the clinical evolution of 156 patients with cirrhosis and ascites (first or recurrence) with lower than 250 polymorphonuclear cells (PMN)/L, negative ascites bacteriological culture, and absence of other bacterial infections being admitted for evaluation of largevolume paracentesis, according to the presence of bactDNA at admission. Survival, causes of death, and successive hospital admissions were determined during a 12-month follow-up period. BactDNA was detected in 48 patients. T…

AdultDNA BacterialLiver CirrhosisMalemedicine.medical_specialtyCirrhosisNeutrophilsKaplan-Meier EstimatePeritonitisGastroenterologyLiver diseaseSpontaneous bacterial peritonitisRisk FactorsInternal medicineAscitesParacentesisEscherichia coliMedicineAscitic FluidHumansProspective StudiesProspective cohort studyCause of deathAgedAged 80 and overHepatologymedicine.diagnostic_testbusiness.industryIncidenceAscitesHepatologyMiddle Agedmedicine.diseasePrognosisSurgeryMultivariate AnalysisFemalemedicine.symptombusinessLiver FailureFollow-Up StudiesHepatology (Baltimore, Md.)
researchProduct

Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis : A longitudinal study of 1893 biopsy-proven no…

2021

[Background and Aim] Histological score systems may not fully capture the essential nonalcoholic steatohepatitis (NASH) features, which is one of the leading causes of screening failure in clinical trials. We assessed the NASH distribution and its components across the fibrosis stages and their impact on the prognosis and their relationship with the concept of metabolic-associated fatty liver disease (MAFLD).

Liver Cirrhosismedicine.medical_specialtyCirrhosisSteatosisBiopsyGastroenterologydigestive systemBallooning03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFatty liver diseaseInternal medicineBiopsyNonalcoholic fatty liver diseasemedicineassociated fatty liver diseaseMetabolic-associated fatty liver diseaseHumansmetabolic&#8208Longitudinal StudiesFirst episodeInflammationHepatologymedicine.diagnostic_testballooning fatty liver disease inflammation metabolic-associated fatty liver disease natural coursesteatohepatitis steatosisbusiness.industryFatty liverNatural coursesteatohepatitismedicine.diseasedigestive system diseasesLiver030220 oncology & carcinogenesis030211 gastroenterology & hepatologySteatosisSteatohepatitisbusiness
researchProduct